WHO ICTRP trial
Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with…
EUCTR2018-004164-60-NL · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2018-004164-60-NL |
|---|---|
| Public title | Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Variegate Porphyria (VP)-related skin disease |
| Scientific title | A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Variegate Porphyria (VP)-related skin disease. - Phase IIa VP Study |
| Primary sponsor | CLINUVEL (UK) LTD |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Netherlands;Switzerland |
| Conditions | Variegate Porphyria (VP)-related skin disease;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] |
| Interventions | Trade Name: SCENESSE Pharmaceutical Form: Implant |
| Registration date | Feb 21, 2022 |
| Target size | 6 |
| Secondary IDs | CUV040 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: